CD4+ T helper (Th) cells are important regulators of cellular immune response. Newly discovered interleukin (IL)-17-producing CD4+ T cells are known as T helper 17 cells (Th17). They are distinct subset from the T helper type 1 (Th1) and 2 (Th2) lineages. The differentiation of Th17 cells has been intensively studied; however, the role of Th17 cells in different diseases including cancer is still under investigation. Besides IL-17 family cytokines, Th17 cells produce IL-22, IL-21, and IL-26. The dysregulated function of Th17 cells and their cytokines could contribute to pathology of diseases, including cancer. The role of cytokines of Th17 cells such as IL-17, IL-21, and IL-22 in cancer will be discussed in this review.
Get full access to this article
View all access options for this article.
References
1.
AlinejadV, DolatiS, MotallebnezhadM, YousefiM. 2017. The role of IL17B-IL17RB signaling pathway in breast cancer. Biomed Pharmacother, 88:795–803.
2.
BiswasSK, MantovaniA. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol, 11(10):889–896.
3.
BrowningRL, ByrdWH, GuptaN, JonesJ, MoX, HertleinE, YuL, MuthusamyN, ByrdJC. 2016. Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunol Res, 4(8):698–707.
4.
CostanzoA, ChimentiMS, BottiE, CarusoR, SarraM, MonteleoneG. 2010. IL-21 in the pathogenesis and treatment of skin diseases. J Dermatol Sci, 60(2):61–66.
5.
CroceM, RigoV, FerriniS. 2015. IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res, 2015:696578.
6.
DavisMR, ZhuZ, HansenDM, BaiQ, FangY. 2015. The role of IL-21 in immunity and cancer. Cancer Lett, 358(2):107–114.
7.
DoulabiH, RastinM, ShabahanghH, MaddahG, AbdollahiA, NosratabadiR, EsmaeiliSA, MahmoudiM. 2018. Analysis of Th22, Th17 and CD4+ cells co-producing IL-17/IL-22 at different stages of human colon cancer. Biomed Pharmacother, 103:1101–1106.
8.
DuhenT, GeigerR, JarrossayD, LanzavecchiaA, SallustoF. 2009. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol, 10:857–863.
9.
EyerichK, DimartinoV, CavaniA. 2017. IL-17 and IL-22 in immunity: driving protection and pathology. Eur J Immunol, 47(4):607–614.
10.
EyerichS, EyerichK, PenninoD, CarboneT, NasorriF, PallottaS, CianfaraniF, OdorisioT, Traidl-HoffmannC, BehrendtH, DurhamSR, Schmidt-WeberCB, CavaniA. 2009. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest, 119:3573–3585.
11.
FabreJ, GiustinianiJ, GarbarC, AntonicelliF, MerroucheY, BensussanA, BagotM, Al-DacakR. 2016. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci, 17(9). pii: e1433. DOI: 10.3390/ijms17091433.
HagnM, SchwesingerE, EbelV, SontheimerK, MaierJ, BeyerT, SyrovetsT, LaumonnierY, FabriciusD, SimmetT, JahrsdöferB. 2009. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol, 183:1838–1845.
14.
HarringtonLE, HattonRD, ManganPR, TurnerH, MurphyTL, MurphyKM, WeaverCT. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6(11):1123–1132.
15.
HarrisTJ, GrossoJF, YenHR, XinH, KortylewskiM, AlbesianoE, HipkissEL, GetnetD, GoldbergMV, MarisCH, HousseauF, YuH, PardollDM, DrakeCG. 2007. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol, 179:4313–4317.
16.
IvanovII, McKenzieBS, ZhouL, TadokoroCE, LepelleyA, LafailleJJ, CuaDJ, LittmanDR. 2006. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell, 126(6):1121–1133.
17.
JettenAM. 2009. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal, 7:e003.
18.
Kim-SchulzeS, KimHS, FanQ, KimDW, KaufmanHL. 2009. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther, 17(2):380–388.
19.
KornT, BettelliE, GaoW, AwasthiA, JägerA, StromTB, OukkaM, KuchrooVK. 2007. IL-21 initiates an alternative pathway to induce pro-inflammatory T(H)17 cells. Nature, 448:484–487.
20.
KryczekI, BanerjeeM, ChengP, VatanL, SzeligaW, WeiS, HuangE, FinlaysonE, SimeoneD, WellingTH, ChangA, CoukosG, LiuR, ZouW. 2009. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 114:1141–1149.
21.
LeeMH, Tung-Chieh ChangJ, LiaoCT, ChenYS, KuoML, ShenCR. 2018. Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients. Oncotarget, 9(11):9825–9837.
LiA, GanY, WangR, LiuY, MaT, HuangM, CuiX. 2015. IL-22 up-regulates β-defensin-2 expression in human alveolar epithelium via STAT3 but not NF-κB signaling pathway. Inflammation, 38(3):1191–1200.
24.
LindnerS, DahlkeK, SontheimerK, HagnM, KaltenmeierC, BarthTF, BeyerT, ReisterF, FabriciusD, LotfiR, LunovO, NienhausGU, SimmetT, KreienbergR, MöllerP, SchrezenmeierH, JahrsdörferB. 2013. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res, 73(8):2468–2479.
25.
NardinocchiL, SonegoG, PassarelliF, AvitabileS, ScarponiC, FaillaCM, SimoniS, AlbanesiC, CavaniA. 2015. Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol, 45:922–931.
26.
NurievaR, YangXO, MartinezG, ZhangY, PanopoulosAD, MaL, SchlunsK, TianQ, WatowichSS, JettenAM, DongC. 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature, 448:480–483.
27.
ParksOB, PociaskDA, HodzicZ, KollsJK, GoodM. 2016. Interleukin-22 signaling in the regulation of intestinal health and disease. Front Cell Dev Biol, 3:85.
28.
PuntS, FleurenGJ, KritikouE, LubbertsE, TrimbosJB, JordanovaES, GorterA. 2015a. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology, 4(1):e984539.
29.
PuntS, LangenhoffJM, PutterH, FleurenGJ, GorterA, JordanovaES. 2015b. The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology, 4:e984547.
30.
QianX, ChenH, WuX, HuL, HuangQ, JinY. 2017. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine, 89:34–44.
31.
RutzS, EidenschenkC, OuyangW. 2013. IL-22, not simply a Th17 cytokine. Immunol Rev, 252:116–132.
32.
SøndergaardH, GalsgaardED, BartholomaeussenM, StratenPT, OdumN, SkakK. 2010. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. J Immunother, 33(3):236–249.
33.
SongX, QianY. 2013. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal, 25(12):2335–2347.
34.
SpolskiR, LeonardWJ. 2008. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol, 26:57–79.
35.
TosoliniM, KirilovskyA, MlecnikB, FredriksenT, MaugerS, BindeaG, BergerA, BrunevalP, FridmanWH, PagèsF, GalonJ. 2011. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res, 71:1263–1271.
36.
VeldhoenM, HockingRJ, AtkinsCJ, LocksleyRM, StockingerB. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity, 24:179–189.
37.
VoigtC, MayP, GottschlichA, MarkotaA, WenkD, GerlachI, VoigtS, StathopoulosGT, ArendtKAM, HeiseC, RatajF, JanssenKP, KönigshoffM, WinterH, HimslI, ThaslerWE, SchnurrM, RothenfußerS, EndresS, KoboldS. 2017. Cancer cells induce interleukin 22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. Proc Natl Acad Sci U S A, 114(49):12994–12999.
38.
VolpeE, ServantN, ZollingerR, BogiatziSI, HupéP, BarillotE, SoumelisV. 2008. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol, 9(6):650–657.
39.
WenZ, LiaoQ, ZhaoJ, HuY, YouL, LuZ, JiaC, WeiY, ZhaoY. 2014. High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma. Ann Surg Oncol, 21:125–132.
40.
XuM, LiuM, DuX, LiS, LiH, LiX, LiY, WangY, QinZ, FuYX, WangS. 2015. Intratumoral delivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype. J Immunol, 194(10):4997–5006.
41.
ZhuangY, PengLS, ZhaoYL, ShiY, MaoXH, GuoG, ChenW, LiuXF, ZhangJY, LiuT, LuoP, YuPW, ZouQM. 2012. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother, 61:1965–1975.
42.
ZouW, RestifoNP. 2010. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol, 10:248–256.
